FULC vs GENB

Fulcrum Therapeutics, Inc. vs Generate Biomedicines, Inc. — Valuation Comparison 2026

FULC

Biotechnology
Fulcrum Therapeutics, Inc.
Quality
6.5
out of 10
Value Trap
18
SAFE
Price
$6.82
Last close
Models
9/13
Active
VS

GENB

Biotechnology
Generate Biomedicines, Inc.
Quality
1.8
out of 10
Value Trap
Price
$13.09
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType FULC Fair ValueFULC Upside GENB Fair ValueGENB Upside
Bayesian DCF Intrinsic $2.23 -67.3% $3.47 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.36 -94.5% $0.66 -95.9%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $6.52 -4.4% $8.93 -31.7%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for FULC vs GENB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

FULC vs GENB — Which Stock Is More Undervalued?

FULC scores higher with a 6.5/10 quality rating vs GENB's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Fulcrum Therapeutics, Inc. (FULC) and Generate Biomedicines, Inc. (GENB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

FULC currently trades at $6.82 with a QOC of 6.5/10, while GENB trades at $13.09 with a QOC of 1.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).